# Patient-Trial Match Report

*Generated: 2026-01-05 18:29:13*

## Patient Profile

- **Age**: 61
- **Sex**: Male
- **Cancer Type**: colorectal cancer
- **Biomarkers**: KRAS G12C

**Clinical Description**:
> 61-year-old male with metastatic colorectal adenocarcinoma (sigmoid primary), KRAS G12C mutated, microsatellite stable (MSS). Initial FOLFOX + bevacizumab x12 cycles achieved stable disease. Second-line FOLFIRI + bevacizumab with progression after 4 cycles. Now seeking third-line options. Liver-dominant metastatic disease (6 lesions, largest 3.2cm). No peritoneal carcinomatosis. Good appetite, mild fatigue. CEA trending up (45 -> 82 over 2 months). Labs: mild transaminase elevation (AST 52, ALT 48), otherwise normal.

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 12
- **Total trials evaluated**: 100
- **Excluded by fast filter**: 39
- **LLM scored**: 61

## ðŸŸ¢ HIGH Likelihood (21 trials)

### [NCT06149481](https://clinicaltrials.gov/study/NCT06149481)

**Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically confirmed colorectal cancer
- Evidence of metastatic disease
- Received two lines of standard systemic therapy (FOLFOX, FOLFIRI)
- Age >= 18 years
- ECOG performance status 1
- Measurable disease per RECIST 1.1
- No brain metastases

**? Uncertainties:**
- Function lab results for absolute neutrophil count, platelet count, hemoglobin, total bilirubin, creatinine clearance

**Assessment:**
> The patient's colorectal cancer matches the trial's indication, and the patient has received the required prior therapies, meeting major criteria. There are some uncertainties regarding organ function lab results, but the patient fulfills the majority of eligibility requirements.

---

### [NCT06412198](https://clinicaltrials.gov/study/NCT06412198)

**A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations**

- **Sponsor**: M.D. Anderson Cancer Center
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically confirmed diagnosis of metastatic colorectal cancer with KRAS G12C mutation
- ECOG status of 1
- Received 2 prior lines of therapy with documented progression
- Age is 61, which is above the minimum age requirement of 18
- Willingness to participate in study-related procedures
- Liver-dominant metastatic disease with measurable lesions

**? Uncertainties:**
- Exact values for absolute neutrophil count, platelet count, hemoglobin, total bilirubin, AST, ALT, and creatinine clearance are not provided

**Assessment:**
> The patient's cancer type and biomarker match the trial's focus on KRAS G12C mutated metastatic colorectal cancer. The patient is also previously treated, aligning with the trial's inclusion criteria. The only uncertainties exist regarding specific lab values, which do not fundamentally conflict with eligibility.

---

### [NCT04929223](https://clinicaltrials.gov/study/NCT04929223)

**A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)**

- **Sponsor**: Hoffmann-La Roche
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic colorectal adenocarcinoma.
- Patient has KRAS G12C mutation.
- ECOG status of 1.
- Patient has previously received FOLFOX, bevacizumab, and FOLFIRI.
- Patient has liver-dominant metastatic disease.
- Patient has a life expectancy of >= 3 months (implied).
- No brain metastases.

**? Uncertainties:**
- Adequate hematologic and organ function within 14 days prior to initiation of study treatment (labs details not fully provided).

**Assessment:**
> The patient's cancer type matches the trial's objective of studying metastatic colorectal cancer. The patient has received prior therapies, aligning with the trial's focus on previously treated patients. There are no significant conflicts with eligibility criteria, and while there are minor uncertainties regarding lab results, the overall profile supports a high likelihood of eligibility.

---

### [NCT06562192](https://clinicaltrials.gov/study/NCT06562192)

**Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers**

- **Sponsor**: Novartis Pharmaceuticals
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic colorectal cancer, which is included in the trial study conditions.
- Patient has already received two lines of therapy (FOLFOX + bevacizumab and FOLFIRI + bevacizumab), indicating he is previously treated.
- Patient is male and aged 61, meeting the age requirement stated in the trial.

**? Uncertainties:**
- Need to confirm if lesions show 68Ga-NNS309 uptake, as this is a requirement in the trial.

**Assessment:**
> The patient's cancer type matches the trial and he has received prior treatment, making him eligible as a previously treated patient. There is a small uncertainty regarding biomarker uptake, but overall he meets the critical eligibility criteria.

---

### [NCT04956640](https://clinicaltrials.gov/study/NCT04956640)

**A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors**

- **Sponsor**: Eli Lilly and Company
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type matches trial conditions as colorectal cancer is included.
- Patient has a KRAS G12C mutation which is required for eligibility.
- ECOG status is 1, meeting the trial requirement.

**? Uncertainties:**
- Adequate organ function is uncertain as specific lab values for organ function are not provided.
- Confirmation on whether all previous treatments for cancer have resolved any significant ongoing adverse events (AEs) is uncertain.

**Assessment:**
> The patient's colorectal cancer type matches the trial's indications. They have a KRAS G12C mutation, are classified as ECOG 1, and no conflict prevents eligibility. The uncertainties mainly revolve around organ function labs and resolution of prior treatment effects, but do not significantly detract from a strong likelihood of eligibility.

---

### [NCT01174121](https://clinicaltrials.gov/study/NCT01174121)

**A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic colorectal cancer, which is included in the trial conditions.
- Patient has received oxaliplatin (FOLFOX) in prior therapies and is considered refractory.
- Patient is 61 years old and has an ECOG status of 1.
- No brain metastases present.
- Patient is willing to sign a written informed consent document.

**? Uncertainties:**
- Need for confirmation of diagnostic criteria by the NCI Laboratory of Pathology (not provided).
- Organ function lab results for ANC, WBC, Platelet count, Hemoglobin, and liver function tests (ALT, AST, total bilirubin) have mild elevation and need verification against criteria.

**Assessment:**
> The patient's cancer type matches the trial's conditions, and he has received prior therapies, qualifying him as previously treated. Age and ECOG status are appropriate, with no issues related to brain metastases. However, some lab results need confirmation for full eligibility validation, preventing complete certainty.

---

### [NCT05410145](https://clinicaltrials.gov/study/NCT05410145)

**A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation**

- **Sponsor**: D3 Bio (Wuxi) Co., Ltd
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has histologically confirmed metastatic colorectal cancer.
- Patient has a documented KRAS G12C mutation.
- Patient has ECOG status of 1.
- Patient has measurable disease per RECIST v1.1.

**? Uncertainties:**
- Adequate organ and marrow function is not explicitly confirmed (lab values for organ function are reported as mild abnormality).

**Assessment:**
> The patient's disease type (colorectal cancer with KRAS G12C mutation) aligns with the study's focus, and he has a performance status and measurable disease that match eligibility criteria. Although there is a minor uncertainty regarding organ function, overall eligibility appears strong.

---

### [NCT05786924](https://clinicaltrials.gov/study/NCT05786924)

**A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies**

- **Sponsor**: Institut de Recherches Internationales Servier
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has advanced/metastatic colorectal cancer
- Patient has KRAS G12C mutation
- Patient's ECOG status is 1
- Patient's age is 61

**? Uncertainties:**
- Patient's organ function is not explicitly confirmed in the lab results

**Assessment:**
> The patient's disease type is colorectal cancer, which is included in the trial. The patient is previously treated, which aligns with the trial's design. They have the required KRAS G12C biomarker, and their ECOG status and age are acceptable. The only uncertainty resides in the confirmation of organ function, which is not explicitly detailed.

---

### [NCT06244771](https://clinicaltrials.gov/study/NCT06244771)

**An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors**

- **Sponsor**: Frontier Medicines Corporation
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic colorectal cancer, which matches the trial condition of colorectal cancer.
- Patient has KRAS G12C mutation, which is required by the trial.
- ECOG status is 1, which is acceptable for the trial.
- Patient has received prior therapies and is now seeking third-line options, which aligns with being previously treated.

**? Uncertainties:**
- Adequate hematological, renal, and hepatic function cannot be completely confirmed due to mild transaminase elevation (AST 52, ALT 48) without further lab details.
- No brain metastases is confirmed, but there is no information provided regarding potential contraindications about other illnesses or medical history.

**Assessment:**
> The patient's cancer type and biomarker match the trial criteria, and their treatment history indicates they are eligible for previously treated patients. While there are some uncertainties regarding lab results and medical history, the significant supporting factors suggest a high likelihood of eligibility.

---

### [NCT07223047](https://clinicaltrials.gov/study/NCT07223047)

**A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies**

- **Sponsor**: Bristol-Myers Squibb
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has a histologically confirmed diagnosis of colorectal cancer.
- Patient has a KRAS G12C mutation.
- Patient has previously received standard of care treatments.

**? Uncertainties:**
- PD-L1 expression status is not provided.

**Assessment:**
> The patient's cancer type matches the trial's focus on colorectal cancer, and the patient has the required KRAS mutation. The patient has received prior therapies, which aligns with the criteria for previously treated patients. However, lacking information on PD-L1 expression introduces a minor uncertainty.

---

### [NCT04511039](https://clinicaltrials.gov/study/NCT04511039)

**A Phase I Study of Trifluridine/ Tipiracil Plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced Cancers**

- **Sponsor**: Roswell Park Cancer Institute
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically confirmed metastatic colorectal adenocarcinoma
- ECOG status of 1
- Has received at least one prior line of therapy with progression
- Measurable disease present with liver lesions
- Life expectancy assessed as >= 3 months by investigator
- Hemoglobin >= 9 g/dL
- Absolute neutrophil count is likely >= 1500/mm^3
- Platelet count is likely >= 100,000/mm^3
- Creatinine < 1.5 ULN or clearance likely > 60 mL/min
- AST 52, ALT 48, which are <= 2.5 x ULN for liver metastasis
- Ability to swallow oral medications

**Assessment:**
> The patient's cancer type of metastatic colorectal adenocarcinoma matches the trial's focus on metastatic colorectal cancer. The patient has received prior therapies as required and has an ECOG status of 1, making them eligible under standard criteria.

---

### [NCT05067283](https://clinicaltrials.gov/study/NCT05067283)

**A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors**

- **Sponsor**: Merck Sharp & Dohme LLC
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically confirmed diagnosis of locally advanced unresectable or metastatic colorectal adenocarcinoma
- Histologically confirmed KRAS G12C mutation
- Previous treatment failure of at least 2 previous lines of systemic therapy

**? Uncertainties:**
- No organ function labs provided in the patient profile

**Assessment:**
> The patient has a directly matching cancer type (colorectal adenocarcinoma), with confirmed KRAS G12C mutation, and has failed at least two lines of systemic therapy. The only uncertainty is regarding organ function, but overall, the patient likely qualifies for the trial.

---

### [NCT06026410](https://clinicaltrials.gov/study/NCT06026410)

**Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors**

- **Sponsor**: Kura Oncology, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient is 61 years old.
- Patient has colorectal cancer, matching the trial's conditions studied.
- Patient has KRAS G12C mutation, which fits the requirements for Arm #3.
- Patient has received prior systemic therapies.
- Patient has an ECOG status of 1.
- Patient has liver-dominant metastatic disease with measurable lesions.

**? Uncertainties:**
- Liver function lab results are mildly elevated but not within the context of total acceptable function.
- Details on current systemic therapy or time since last treatment could affect eligibility.

**Assessment:**
> The patient's colorectal cancer aligns with the trial's focus on solid tumors, specifically CRC, and their KRAS G12C mutation qualifies them for treatment as outlined in Arm #3. They have a history of prior systemic therapies and suitable ECOG status, indicating that they likely meet the inclusion criteria.

---

### [NCT06128551](https://clinicaltrials.gov/study/NCT06128551)

**Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors**

- **Sponsor**: Revolution Medicines, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has colorectal cancer, which is one of the conditions studied in the trial.
- Patient has a KRAS G12C mutation, which is required for this trial.
- Patient's ECOG status is 1, meeting the trial's requirement.
- Patient has been previously treated with systemic therapies, which aligns with the trial's eligibility for previously treated patients.
- Patient has no brain metastases, complying with trial exclusion criteria.

**? Uncertainties:**
- Need to confirm adequate organ function based on provided lab values.
- Minor uncertainties regarding specific thresholds for organ function tests (e.g., transaminase elevation).

**Assessment:**
> The patient's cancer type is aligned with the trial, and he meets the criteria for previously treated patients with the required biomarkers and ECOG status. There are uncertainties regarding organ function test thresholds, but the core eligibility criteria are satisfied.

---

### [NCT06447662](https://clinicaltrials.gov/study/NCT06447662)

**A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene**

- **Sponsor**: Pfizer
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Diagnosis of metastatic colorectal adenocarcinoma
- ECOG status of 1
- Confirmed KRAS mutation (G12C)
- Progressed on prior lines of systemic therapy for mCRC

**? Uncertainties:**
- Laboratory values regarding hepatic abnormalities

**Assessment:**
> The patient's cancer type (metastatic colorectal cancer) matches the trial's conditions. He has a KRAS mutation and has progressed on prior therapies which fits the previously treated patient criteria. The only uncertainty lies in his hepatic function due to mild transaminase elevation.

---

### [NCT06403436](https://clinicaltrials.gov/study/NCT06403436)

**A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors**

- **Sponsor**: TOLREMO therapeutics AG
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age 61, meets age requirement (â‰¥ 18 years)
- ECOG status 1, which is acceptable
- Patient has advanced solid tumor (colorectal cancer) that is refractory to standard treatment
- Measurable disease present with liver lesions

**? Uncertainties:**
- Absolute neutrophil count, platelet count, hemoglobin levels are not provided
- Creatinine clearance is not provided

**Assessment:**
> The patient's cancer type of colorectal cancer matches the trial's indication for advanced solid tumors, and he is refractory to prior treatments making him eligible based on cancer status. The only uncertainties are minor lab values relevant to organ function, but overall, he meets the major eligibility criteria.

---

### [NCT06720987](https://clinicaltrials.gov/study/NCT06720987)

**A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Optimization Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB365 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations**

- **Sponsor**: Kumquat Biosciences Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically confirmed diagnosis of metastatic colorectal adenocarcinoma
- KRAS G12C mutation
- Unresectable or metastatic disease
- No available treatment with curative intent
- ECOG status 1

**? Uncertainties:**
- Organ function based on lab values (AST 52, ALT 48) is mildly elevated but not clearly disqualifying

**Assessment:**
> The patient's cancer type (colorectal cancer) matches the trial's target indication, and the patient has the required KRAS G12C mutation. The patient is in need of third-line treatment after previous therapies, aligning with the trial's enrollment of previously treated patients. The ECOG status and absence of brain metastases further support eligibility.

---

### [NCT06607185](https://clinicaltrials.gov/study/NCT06607185)

**A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors**

- **Sponsor**: Eli Lilly and Company
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic colorectal cancer which is one of the conditions studied.
- Patient has KRAS G12C mutation, which is required for trial eligibility.
- Patient has ECOG performance status of 1, which meets the trial requirement of â‰¤1.
- Patient has measurable disease per RECIST 1.1 as indicated by liver lesions.

**? Uncertainties:**
- Patient's organ function is not detailed; AST and ALT are mildly elevated, but further verification of liver function is needed.
- No information provided on the exact definition of measurable disease criteria verification.

**Assessment:**
> The patient has metastatic colorectal cancer that aligns with the trial's indications, has the required KRAS mutation, and meets the ECOG status requirement. The treatment line is suitable as the trial allows previously treated patients. Minor uncertainties exist concerning organ function and detailed measurable disease verification.

---

### [NCT06917079](https://clinicaltrials.gov/study/NCT06917079)

**A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers**

- **Sponsor**: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic colorectal cancer, which is a target condition of the trial.
- Patient has KRAS G12C mutation, which is one of the specified biomarkers for inclusion.
- Patient's ECOG status is 1, which meets the trial criterion of ECOG PS 0-1.
- Patient has measurable disease with multiple liver lesions.

**? Uncertainties:**
- No specific information on organ function tests other than mild transaminase elevation.

**Assessment:**
> The patient's colorectal cancer diagnosis aligns with the trial's focus on metastatic colorectal cancer. The patient's KRAS G12C mutation and ECOG status meet the inclusion criteria. Though the patient has received prior treatments, the trial does not specify that it is limited to treatment-naive patients, and the available data supports inclusion.

---

### [NCT06910657](https://clinicaltrials.gov/study/NCT06910657)

**A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors**

- **Sponsor**: ViroMissile, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age is 61, which is â‰¥ 18 years.
- ECOG status is 1, which is â‰¤ 1.
- Patient has an advanced solid tumor (colorectal cancer) that has progressed despite standard therapy.
- No brain metastases.
- Patient has a measurable disease (liver-dominant metastatic disease).

**? Uncertainties:**
- Adequate organ function and bone marrow function are not explicitly confirmed in the profile.
- Details on whether the patient has had any recent infections or treatments that might affect eligibility are not provided.

**Assessment:**
> The patient's colorectal cancer matches the trial's condition. He is well beyond first-line therapy, as evidenced by prior treatments. There are minor uncertainties regarding organ function but no critical exclusion factors.

---

### [NCT07094204](https://clinicaltrials.gov/study/NCT07094204)

**A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications**

- **Sponsor**: Astellas Pharma Inc
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has histologically confirmed metastatic colorectal adenocarcinoma.
- Patient has a documented KRAS G12C mutation.
- Patient has an ECOG performance status of 1.
- Patient has received prior standard therapy including FOLFOX and FOLFIRI.
- Patient has no brain metastases.

**? Uncertainties:**
- Liver function tests indicate mild elevation but are not categorized as normal or abnormal.
- No specific measurable lesion assessment data (e.g., RECIST criteria) provided.

**Assessment:**
> The patient has metastatic colorectal cancer with a KRAS G12C mutation, matching the trial's indication. He has been treated previously, aligning with the trial criteria, and his ECOG status is acceptable. Minor uncertainties include lab values and measurable lesions.

---

## ðŸŸ¡ MEDIUM Likelihood (1 trials)

### [NCT06997497](https://clinicaltrials.gov/study/NCT06997497)

**A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)**

- **Sponsor**: Merck Sharp & Dohme LLC
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Patient has a histologically confirmed diagnosis of metastatic colorectal adenocarcinoma.
- Patient has a KRAS G12C mutation.

**âœ— Potential Conflicts:**
- Patient has received prior systemic therapies (FOLFOX, bevacizumab, FOLFIRI) which may conflict with inclusion criteria requiring treatment-naive patients.

**? Uncertainties:**
- Liver function tests (AST, ALT) are mildly elevated but not clearly outside acceptable limits.
- No specific details provided regarding HIV or Hepatitis B/C status.

**Assessment:**
> The patient has the correct cancer type and the required biomarker but has had prior systemic therapy, which might conflict with the trial's eligibility criteria for treatment-naive patients.

---

## Excluded (78 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT06342401](https://clinicaltrials.gov/study/NCT06342401) | Patient age 61 is above maximum age 50 |
| [NCT02448173](https://clinicaltrials.gov/study/NCT02448173) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04165772](https://clinicaltrials.gov/study/NCT04165772) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04302025](https://clinicaltrials.gov/study/NCT04302025) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04589845](https://clinicaltrials.gov/study/NCT04589845) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05405595](https://clinicaltrials.gov/study/NCT05405595) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05638295](https://clinicaltrials.gov/study/NCT05638295) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05722288](https://clinicaltrials.gov/study/NCT05722288) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05952557](https://clinicaltrials.gov/study/NCT05952557) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05961709](https://clinicaltrials.gov/study/NCT05961709) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06730750](https://clinicaltrials.gov/study/NCT06730750) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06881784](https://clinicaltrials.gov/study/NCT06881784) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT07223424](https://clinicaltrials.gov/study/NCT07223424) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT07227025](https://clinicaltrials.gov/study/NCT07227025) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT07288034](https://clinicaltrials.gov/study/NCT07288034) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT00034216](https://clinicaltrials.gov/study/NCT00034216) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT02012699](https://clinicaltrials.gov/study/NCT02012699) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT02172651](https://clinicaltrials.gov/study/NCT02172651) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03203525](https://clinicaltrials.gov/study/NCT03203525) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03260491](https://clinicaltrials.gov/study/NCT03260491) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| ... | *and 19 more* |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT06252649](https://clinicaltrials.gov/study/NCT06252649) | Amgen | Patient is not treatment-naive; has previously received FOLFOX + bevacizumab and FOLFIRI. |
| [NCT03998202](https://clinicaltrials.gov/study/NCT03998202) | Wake Forest Universi | Patient has prior systemic chemotherapy for metastatic colorectal cancer; trial requires newly diagnosed metastatic CRC or metastatic recurrence > 3 months from last treatment. |
| [NCT04899908](https://clinicaltrials.gov/study/NCT04899908) | Dana-Farber Cancer I | Patient has colorectal cancer, but trial is for brain metastases and does not specify acceptable criteria for colorectal cancer besides brain metastases. |
| [NCT05853575](https://clinicaltrials.gov/study/NCT05853575) | Mirati Therapeutics  | Patient has colorectal cancer, but the trial is for NSCLC. |
| [NCT07190248](https://clinicaltrials.gov/study/NCT07190248) | Merck Sharp & Dohme  | Patient has colorectal cancer, while trial is for non-small cell lung cancer (NSCLC). |
| [NCT07262619](https://clinicaltrials.gov/study/NCT07262619) | Eikon Therapeutics | Patient has KRAS G12C mutated colorectal cancer which is microsatellite stable (MSS), while the trial is focused on MSI-H or dMMR tumors. |
| [NCT03551951](https://clinicaltrials.gov/study/NCT03551951) | University of Missou | Patient has metastatic colorectal cancer, but the trial is primarily focused on early-stage solid tumors and does not specify inclusion of advanced/metastatic disease. |
| [NCT04314401](https://clinicaltrials.gov/study/NCT04314401) | National Cancer Inst | Trial does not specifically include colorectal cancer as a target indication unless it is stage IV; however, the patient has stage IV colorectal cancer. |
| [NCT04633512](https://clinicaltrials.gov/study/NCT04633512) | Activ Surgical | Patient's cancer type is colorectal cancer which does match the trial conditions, but given the specifications of surgical resection and the patient's current stage, he may not be eligible. |
| [NCT06096623](https://clinicaltrials.gov/study/NCT06096623) | UNC Lineberger Compr | Patient has previously received cancer treatment (FOLFOX, bevacizumab, FOLFIRI), while the trial requires patients who have not yet initiated cancer treatment. |
| [NCT07115875](https://clinicaltrials.gov/study/NCT07115875) | University of Oklaho | Patient's cancer type is colorectal cancer, but the trial focuses on improving diagnostic outreach specifically for Native Americans which does not match the patient's profile. |
| [NCT07225309](https://clinicaltrials.gov/study/NCT07225309) | Memorial Sloan Kette | Trial specifically mentioning treatment for Mexican patients, while patient is in the United States |
| [NCT06130254](https://clinicaltrials.gov/study/NCT06130254) | M.D. Anderson Cancer | Patient has colorectal cancer, while trial is focused on patients with advanced solid tumors specifically targeting KRAS G12C in pancreatic cancer, breast cancer, gynecological cancers, and non-small cell lung cancer. |
| [NCT06634875](https://clinicaltrials.gov/study/NCT06634875) | Buzzard Pharmaceutic | Tumor mutational burden (TMB) must be high (TMB-H) but patient is microsatellite stable (MSS) which does not indicate high TMB |
| [NCT06822530](https://clinicaltrials.gov/study/NCT06822530) | Fred Hutchinson Canc | Trial studies interventions for abnormal, non-invasive colorectal cancer screening tests, while patient has metastatic colorectal cancer requiring treatment. |
| [NCT07046585](https://clinicaltrials.gov/study/NCT07046585) | Natera, Inc. | Trial is for participants at average risk for colorectal cancer; patient has metastatic colorectal cancer. |
| [NCT07023731](https://clinicaltrials.gov/study/NCT07023731) | Arvinas Inc. | Patient has KRAS G12C mutation, but trial requires KRAS G12D mutation. |
| [NCT06890598](https://clinicaltrials.gov/study/NCT06890598) | Eli Lilly and Compan | Patient has colorectal cancer while trial is for non-small cell lung cancer (NSCLC) |
| [NCT07221357](https://clinicaltrials.gov/study/NCT07221357) | Bristol-Myers Squibb | Patient is previously treated with FOLFOX and FOLFIRI, while trial is for previously untreated colorectal cancer. |
| [NCT06746012](https://clinicaltrials.gov/study/NCT06746012) | Ohio State Universit | Patient has metastatic colorectal cancer (stage IV), while the trial only includes patients with stage I-III colon or rectal cancer. |
| ... | ... | *and 19 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| KRAS G12C | manual | 1.0 |
| KRASG12C | manual | 0.9 |
| KRAS-G12C | manual | 0.9 |
| colorectal cancer | manual | 1.0 |
| KRAS G12C colorectal cancer | manual | 1.0 |
| KRAS G12C metastatic colorectal cancer | llm | 0.9 |
| KRAS G12C adenocarcinoma | llm | 0.9 |
| colon cancer | llm | 0.8 |
| colorectal adenocarcinoma | llm | 0.8 |
| KRAS p.G12C | llm | 0.9 |
| KRASp.G12C | llm | 0.8 |
| KRAS-p.G12C | llm | 0.8 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **PD-L1 expression status** - required by several trials for cohort assignment
- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Measurable disease status** (per RECIST 1.1) - required for most therapeutic trials
